/**
 * Medications Question Bank
 *
 * 100+ questions on drug mechanisms, side effects, interactions, and clinical applications.
 */

import type { QuizQuestion } from './types';

export const medicationQuestions: QuizQuestion[] = [
  // CARDIAC MEDICATIONS
  {
    questionId: 'med-card-001',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'cardiovascular',
    difficulty: 1,
    questionText: 'What is the mechanism of action of aspirin in preventing heart attacks?',
    choices: [
      { choiceId: 'a', text: 'Irreversible inhibition of cyclooxygenase (COX)', isCorrect: true, explanation: 'Aspirin acetylates COX, preventing thromboxane A2 synthesis.' },
      { choiceId: 'b', text: 'Blocking vitamin K', isCorrect: false, explanation: 'Warfarin blocks vitamin K, not aspirin.' },
      { choiceId: 'c', text: 'Inhibiting thrombin directly', isCorrect: false, explanation: 'Dabigatran directly inhibits thrombin.' },
      { choiceId: 'd', text: 'Activating antithrombin III', isCorrect: false, explanation: 'Heparin activates antithrombin III.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Aspirin irreversibly inhibits COX.',
      detailed: 'Aspirin acetylates COX-1 in platelets, preventing thromboxane A2 production for the platelet lifetime (7-10 days). TXA2 promotes platelet aggregation and vasoconstriction.',
      clinicalRelevance: 'Low-dose aspirin (81 mg) is used for secondary prevention in cardiovascular disease. Aspirin resistance exists in some patients.',
      relatedConcepts: ['platelet function', 'antiplatelet therapy', 'COX enzymes'],
    },
    tags: ['aspirin', 'antiplatelet', 'beginner'],
    relatedTopicIds: ['antiplatelet-drugs', 'CAD-prevention'],
  },
  {
    questionId: 'med-card-002',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'cardiovascular',
    difficulty: 2,
    questionText: 'Which class of antihypertensives works by blocking L-type calcium channels?',
    choices: [
      { choiceId: 'a', text: 'Calcium channel blockers (amlodipine, diltiazem)', isCorrect: true, explanation: 'CCBs block L-type Ca channels in vascular smooth muscle and heart.' },
      { choiceId: 'b', text: 'Beta blockers', isCorrect: false, explanation: 'Beta blockers block adrenergic receptors.' },
      { choiceId: 'c', text: 'ACE inhibitors', isCorrect: false, explanation: 'ACE inhibitors block angiotensin-converting enzyme.' },
      { choiceId: 'd', text: 'Thiazide diuretics', isCorrect: false, explanation: 'Thiazides block Na-Cl cotransporter in DCT.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Calcium channel blockers block L-type Ca channels.',
      detailed: 'Dihydropyridines (amlodipine) primarily affect vascular smooth muscle causing vasodilation. Non-dihydropyridines (diltiazem, verapamil) also affect cardiac tissue, slowing HR and conduction.',
      clinicalRelevance: 'CCBs are first-line for hypertension. Avoid non-DHP CCBs with beta blockers (risk of heart block). Constipation and edema are common side effects.',
      relatedConcepts: ['hypertension treatment', 'vascular smooth muscle', 'arrhythmia management'],
    },
    tags: ['CCB', 'antihypertensive', 'intermediate'],
    relatedTopicIds: ['antihypertensives', 'calcium-channels'],
  },
  {
    questionId: 'med-card-003',
    domain: 'pharmacology',
    type: 'side-effects',
    format: 'multiple-choice',
    system: 'cardiovascular',
    difficulty: 2,
    questionText: 'Which side effect is characteristic of ACE inhibitors?',
    choices: [
      { choiceId: 'a', text: 'Dry cough', isCorrect: true, explanation: 'ACE inhibitors cause cough due to bradykinin accumulation.' },
      { choiceId: 'b', text: 'Constipation', isCorrect: false, explanation: 'Constipation is common with CCBs and opioids.' },
      { choiceId: 'c', text: 'Bronchospasm', isCorrect: false, explanation: 'Bronchospasm is seen with beta blockers.' },
      { choiceId: 'd', text: 'Gynecomastia', isCorrect: false, explanation: 'Gynecomastia is seen with spironolactone.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'ACE inhibitors cause dry cough due to bradykinin.',
      detailed: 'ACE degrades bradykinin. When ACE is inhibited, bradykinin accumulates in lungs, causing cough in 5-20% of patients. Angioedema is a rare but serious adverse effect.',
      clinicalRelevance: 'If cough is intolerable, switch to ARB. ARBs do not cause cough. Both ACE-I and ARBs cause hyperkalemia and are contraindicated in pregnancy.',
      relatedConcepts: ['RAAS inhibitors', 'bradykinin', 'ARBs'],
    },
    tags: ['ACE-inhibitor', 'side-effects', 'intermediate'],
    relatedTopicIds: ['RAAS-inhibitors', 'hypertension-treatment'],
  },
  {
    questionId: 'med-card-004',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'cardiovascular',
    difficulty: 2,
    questionText: 'How do beta blockers reduce blood pressure?',
    choices: [
      { choiceId: 'a', text: 'Decrease heart rate, contractility, and renin release', isCorrect: true, explanation: 'Beta blockers have negative chronotropic, inotropic effects and reduce renin.' },
      { choiceId: 'b', text: 'Direct vasodilation', isCorrect: false, explanation: 'Most beta blockers do not directly dilate vessels (except carvedilol, labetalol).' },
      { choiceId: 'c', text: 'Block aldosterone receptors', isCorrect: false, explanation: 'Spironolactone blocks aldosterone receptors.' },
      { choiceId: 'd', text: 'Increase sodium excretion', isCorrect: false, explanation: 'Diuretics increase sodium excretion.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Beta blockers decrease HR, contractility, and renin.',
      detailed: 'Beta-1 receptors in the heart mediate positive chronotropy and inotropy. Beta-1 receptors in kidney stimulate renin release. Blocking these reduces cardiac output and RAAS activation.',
      clinicalRelevance: 'First-line for HFrEF (carvedilol, metoprolol succinate, bisoprolol). Avoid in decompensated heart failure. Contraindicated in bronchospastic disease (use cardioselective).',
      relatedConcepts: ['heart failure therapy', 'adrenergic receptors', 'RAAS'],
    },
    tags: ['beta-blocker', 'mechanism', 'intermediate'],
    relatedTopicIds: ['antihypertensives', 'heart-failure-drugs'],
  },
  {
    questionId: 'med-card-005',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'cardiovascular',
    difficulty: 3,
    questionText: 'Digoxin toxicity is enhanced by which electrolyte abnormality?',
    choices: [
      { choiceId: 'a', text: 'Hypokalemia', isCorrect: true, explanation: 'Low K+ increases digoxin binding to Na/K-ATPase.' },
      { choiceId: 'b', text: 'Hyperkalemia', isCorrect: false, explanation: 'High K+ actually reduces digoxin toxicity.' },
      { choiceId: 'c', text: 'Hypernatremia', isCorrect: false, explanation: 'Sodium abnormalities have less effect.' },
      { choiceId: 'd', text: 'Hypophosphatemia', isCorrect: false, explanation: 'Phosphate has minimal effect on digoxin.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Hypokalemia enhances digoxin toxicity.',
      detailed: 'Digoxin inhibits Na+/K+-ATPase. K+ competes with digoxin for binding. Low K+ allows more digoxin binding, increasing toxicity. Hypercalcemia and hypomagnesemia also increase toxicity.',
      clinicalRelevance: 'Monitor K+ in patients on digoxin, especially if also on diuretics. Digoxin toxicity causes arrhythmias, nausea, and visual changes (yellow halos).',
      relatedConcepts: ['digoxin pharmacology', 'cardiac glycosides', 'electrolyte effects'],
    },
    tags: ['digoxin', 'toxicity', 'advanced'],
    relatedTopicIds: ['cardiac-glycosides', 'drug-toxicity'],
  },

  // ANTICOAGULANTS
  {
    questionId: 'med-anticoag-001',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'cardiovascular',
    difficulty: 2,
    questionText: 'What is the mechanism of warfarin?',
    choices: [
      { choiceId: 'a', text: 'Inhibits vitamin K epoxide reductase', isCorrect: true, explanation: 'Warfarin prevents regeneration of reduced vitamin K.' },
      { choiceId: 'b', text: 'Directly inhibits thrombin', isCorrect: false, explanation: 'Dabigatran directly inhibits thrombin.' },
      { choiceId: 'c', text: 'Directly inhibits factor Xa', isCorrect: false, explanation: 'Rivaroxaban and apixaban inhibit factor Xa.' },
      { choiceId: 'd', text: 'Activates antithrombin III', isCorrect: false, explanation: 'Heparin activates antithrombin III.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Warfarin inhibits vitamin K epoxide reductase.',
      detailed: 'Vitamin K is a cofactor for gamma-carboxylation of factors II, VII, IX, X, and proteins C and S. Warfarin prevents vitamin K regeneration, reducing functional clotting factors.',
      clinicalRelevance: 'Monitored by INR (target 2-3 for most indications). Many drug and food interactions. Takes 3-5 days to reach full effect. Reversal: vitamin K, FFP, or PCC.',
      relatedConcepts: ['coagulation cascade', 'INR monitoring', 'anticoagulation reversal'],
    },
    tags: ['warfarin', 'anticoagulant', 'intermediate'],
    relatedTopicIds: ['anticoagulation', 'vitamin-K'],
  },
  {
    questionId: 'med-anticoag-002',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'cardiovascular',
    difficulty: 2,
    questionText: 'Which DOAC directly inhibits thrombin?',
    choices: [
      { choiceId: 'a', text: 'Dabigatran', isCorrect: true, explanation: 'Dabigatran is a direct thrombin inhibitor.' },
      { choiceId: 'b', text: 'Rivaroxaban', isCorrect: false, explanation: 'Rivaroxaban inhibits factor Xa.' },
      { choiceId: 'c', text: 'Apixaban', isCorrect: false, explanation: 'Apixaban inhibits factor Xa.' },
      { choiceId: 'd', text: 'Edoxaban', isCorrect: false, explanation: 'Edoxaban inhibits factor Xa.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Dabigatran directly inhibits thrombin (factor IIa).',
      detailed: 'Dabigatran is a prodrug converted to active form by esterases. It directly inhibits both free and clot-bound thrombin. Renally eliminated (80%), so dose-adjust for renal function.',
      clinicalRelevance: 'Reversal agent: idarucizumab. Can cause dyspepsia. Avoid with CrCl <30. DOACs do not require routine monitoring.',
      relatedConcepts: ['DOACs', 'thrombin', 'anticoagulation management'],
    },
    tags: ['dabigatran', 'DOAC', 'intermediate'],
    relatedTopicIds: ['DOACs', 'anticoagulation'],
  },
  {
    questionId: 'med-anticoag-003',
    domain: 'pharmacology',
    type: 'drug-interaction',
    format: 'multiple-choice',
    system: 'cardiovascular',
    difficulty: 3,
    questionText: 'Which drug significantly increases warfarin effect (INR)?',
    choices: [
      { choiceId: 'a', text: 'Amiodarone', isCorrect: true, explanation: 'Amiodarone inhibits CYP2C9 and CYP3A4, increasing warfarin levels.' },
      { choiceId: 'b', text: 'Rifampin', isCorrect: false, explanation: 'Rifampin induces CYP450, decreasing warfarin effect.' },
      { choiceId: 'c', text: 'Vitamin K', isCorrect: false, explanation: 'Vitamin K antagonizes warfarin, decreasing INR.' },
      { choiceId: 'd', text: 'Phenytoin', isCorrect: false, explanation: 'Phenytoin induces metabolism, decreasing warfarin effect.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Amiodarone increases warfarin effect by inhibiting CYP enzymes.',
      detailed: 'Warfarin is metabolized by CYP2C9 (S-warfarin) and CYP3A4 (R-warfarin). Amiodarone inhibits both enzymes and has a very long half-life (40-55 days), causing prolonged interaction.',
      clinicalRelevance: 'Reduce warfarin dose by 30-50% when starting amiodarone. Monitor INR closely. Effect persists weeks after stopping amiodarone.',
      relatedConcepts: ['CYP450 interactions', 'warfarin management', 'amiodarone'],
    },
    tags: ['warfarin', 'drug-interaction', 'advanced'],
    relatedTopicIds: ['drug-interactions', 'anticoagulation-management'],
  },

  // ANTIBIOTICS
  {
    questionId: 'med-abx-001',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'lymphatic',
    difficulty: 1,
    questionText: 'How do penicillins kill bacteria?',
    choices: [
      { choiceId: 'a', text: 'Inhibit cell wall synthesis', isCorrect: true, explanation: 'Beta-lactams block transpeptidase, preventing peptidoglycan cross-linking.' },
      { choiceId: 'b', text: 'Inhibit protein synthesis', isCorrect: false, explanation: 'Aminoglycosides and macrolides inhibit protein synthesis.' },
      { choiceId: 'c', text: 'Inhibit DNA synthesis', isCorrect: false, explanation: 'Fluoroquinolones inhibit DNA gyrase.' },
      { choiceId: 'd', text: 'Inhibit folate synthesis', isCorrect: false, explanation: 'Sulfonamides and trimethoprim inhibit folate synthesis.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Penicillins inhibit bacterial cell wall synthesis.',
      detailed: 'Beta-lactam antibiotics bind penicillin-binding proteins (transpeptidases), preventing cross-linking of peptidoglycan. This weakens the cell wall, causing lysis. They are bactericidal.',
      clinicalRelevance: 'Resistance via beta-lactamases. Beta-lactamase inhibitors (clavulanate, tazobactam, sulbactam) restore activity. Hypersensitivity reactions are common.',
      relatedConcepts: ['beta-lactams', 'bacterial cell wall', 'antibiotic resistance'],
    },
    tags: ['penicillin', 'antibiotic', 'beginner'],
    relatedTopicIds: ['antibiotics', 'cell-wall-synthesis'],
  },
  {
    questionId: 'med-abx-002',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'lymphatic',
    difficulty: 2,
    questionText: 'Aminoglycosides (gentamicin) work by:',
    choices: [
      { choiceId: 'a', text: 'Binding 30S ribosomal subunit, causing misreading', isCorrect: true, explanation: 'Aminoglycosides cause irreversible binding to 30S, producing faulty proteins.' },
      { choiceId: 'b', text: 'Binding 50S ribosomal subunit', isCorrect: false, explanation: 'Macrolides and chloramphenicol bind 50S.' },
      { choiceId: 'c', text: 'Inhibiting DNA gyrase', isCorrect: false, explanation: 'Fluoroquinolones inhibit DNA gyrase.' },
      { choiceId: 'd', text: 'Blocking cell wall synthesis', isCorrect: false, explanation: 'Beta-lactams block cell wall synthesis.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Aminoglycosides irreversibly bind 30S ribosome.',
      detailed: 'Aminoglycosides bind 30S ribosomal subunit, causing mRNA misreading and premature termination. They are bactericidal and concentration-dependent. Require oxygen for uptake (ineffective against anaerobes).',
      clinicalRelevance: 'Major toxicities: nephrotoxicity and ototoxicity (vestibular and cochlear). Monitor levels and renal function. Once-daily dosing is preferred.',
      relatedConcepts: ['protein synthesis inhibitors', 'aminoglycoside toxicity', 'concentration-dependent killing'],
    },
    tags: ['aminoglycoside', 'antibiotic', 'intermediate'],
    relatedTopicIds: ['protein-synthesis-inhibitors', 'antibiotic-toxicity'],
  },
  {
    questionId: 'med-abx-003',
    domain: 'pharmacology',
    type: 'side-effects',
    format: 'multiple-choice',
    system: 'lymphatic',
    difficulty: 2,
    questionText: 'Which antibiotic class is associated with tendon rupture?',
    choices: [
      { choiceId: 'a', text: 'Fluoroquinolones', isCorrect: true, explanation: 'FQs cause tendinopathy and rupture, especially Achilles tendon.' },
      { choiceId: 'b', text: 'Penicillins', isCorrect: false, explanation: 'Penicillins cause hypersensitivity reactions.' },
      { choiceId: 'c', text: 'Macrolides', isCorrect: false, explanation: 'Macrolides cause QT prolongation and GI upset.' },
      { choiceId: 'd', text: 'Cephalosporins', isCorrect: false, explanation: 'Cephalosporins cause hypersensitivity and disulfiram-like reaction.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Fluoroquinolones cause tendon rupture.',
      detailed: 'FQs affect collagen metabolism, causing tendinopathy and rupture (especially Achilles). Risk increased with age >60, concurrent steroids, kidney disease, and organ transplant.',
      clinicalRelevance: 'FDA black box warning. Also cause peripheral neuropathy, CNS effects, and aortic aneurysm. Reserve for serious infections without alternatives.',
      relatedConcepts: ['fluoroquinolone toxicity', 'antibiotic safety', 'tendon injury'],
    },
    tags: ['fluoroquinolone', 'side-effects', 'intermediate'],
    relatedTopicIds: ['fluoroquinolones', 'drug-safety'],
  },
  {
    questionId: 'med-abx-004',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'lymphatic',
    difficulty: 3,
    questionText: 'Vancomycin is primarily used for:',
    choices: [
      { choiceId: 'a', text: 'MRSA and other gram-positive infections', isCorrect: true, explanation: 'Vancomycin covers MRSA, enterococci, and other resistant gram-positives.' },
      { choiceId: 'b', text: 'Pseudomonas infections', isCorrect: false, explanation: 'Pseudomonas requires anti-pseudomonal agents (piperacillin, cefepime).' },
      { choiceId: 'c', text: 'Anaerobic infections', isCorrect: false, explanation: 'Metronidazole is preferred for anaerobes.' },
      { choiceId: 'd', text: 'Atypical pneumonia', isCorrect: false, explanation: 'Macrolides or doxycycline cover atypicals.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Vancomycin covers MRSA and resistant gram-positives.',
      detailed: 'Vancomycin inhibits cell wall synthesis by binding D-Ala-D-Ala terminus of peptidoglycan precursors. It is only effective against gram-positive organisms (large molecule cannot penetrate gram-negative outer membrane).',
      clinicalRelevance: 'Monitor trough levels (target 10-20 mcg/mL for serious infections). Nephrotoxic, especially with aminoglycosides. Red man syndrome from rapid infusion (histamine release).',
      relatedConcepts: ['MRSA treatment', 'glycopeptides', 'therapeutic drug monitoring'],
    },
    tags: ['vancomycin', 'MRSA', 'advanced'],
    relatedTopicIds: ['gram-positive-coverage', 'antibiotic-stewardship'],
  },

  // ANALGESICS
  {
    questionId: 'med-pain-001',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'nervous',
    difficulty: 1,
    questionText: 'How does acetaminophen (Tylenol) reduce pain?',
    choices: [
      { choiceId: 'a', text: 'Inhibits COX in the CNS', isCorrect: true, explanation: 'Acetaminophen works centrally on COX enzymes, reducing prostaglandins.' },
      { choiceId: 'b', text: 'Blocks opioid receptors', isCorrect: false, explanation: 'Opioids block opioid receptors.' },
      { choiceId: 'c', text: 'Blocks sodium channels', isCorrect: false, explanation: 'Local anesthetics block sodium channels.' },
      { choiceId: 'd', text: 'Inhibits serotonin reuptake', isCorrect: false, explanation: 'SNRIs like duloxetine inhibit serotonin reuptake.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Acetaminophen inhibits COX centrally.',
      detailed: 'The exact mechanism is not fully understood, but acetaminophen likely inhibits COX in the CNS. It has minimal peripheral anti-inflammatory activity. Also may activate descending serotonergic pathways.',
      clinicalRelevance: 'Hepatotoxicity is major concern (max 3-4 g/day). Leading cause of acute liver failure. N-acetylcysteine is antidote for overdose.',
      relatedConcepts: ['COX enzymes', 'hepatotoxicity', 'pain management'],
    },
    tags: ['acetaminophen', 'analgesic', 'beginner'],
    relatedTopicIds: ['pain-medications', 'hepatotoxicity'],
  },
  {
    questionId: 'med-pain-002',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'nervous',
    difficulty: 2,
    questionText: 'Morphine acts on which receptor to produce analgesia?',
    choices: [
      { choiceId: 'a', text: 'Mu (mu) opioid receptor', isCorrect: true, explanation: 'Mu receptors mediate analgesia, euphoria, and respiratory depression.' },
      { choiceId: 'b', text: 'Alpha-2 adrenergic receptor', isCorrect: false, explanation: 'Alpha-2 agonists (clonidine) have analgesic properties but different mechanism.' },
      { choiceId: 'c', text: 'GABA-A receptor', isCorrect: false, explanation: 'Benzodiazepines and barbiturates act on GABA-A.' },
      { choiceId: 'd', text: 'NMDA receptor', isCorrect: false, explanation: 'Ketamine blocks NMDA receptors.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Morphine acts on mu opioid receptors.',
      detailed: 'Mu receptors are G-protein coupled receptors that decrease cAMP, open K+ channels, and close Ca2+ channels, reducing neurotransmitter release. Mu activation causes analgesia, euphoria, respiratory depression, and constipation.',
      clinicalRelevance: 'Respiratory depression is the most dangerous side effect. Naloxone reverses opioid effects. Tolerance and dependence develop with chronic use.',
      relatedConcepts: ['opioid pharmacology', 'pain pathways', 'opioid use disorder'],
    },
    tags: ['opioid', 'mechanism', 'intermediate'],
    relatedTopicIds: ['opioids', 'pain-management'],
  },
  {
    questionId: 'med-pain-003',
    domain: 'pharmacology',
    type: 'side-effects',
    format: 'multiple-choice',
    system: 'nervous',
    difficulty: 2,
    questionText: 'Which opioid side effect does NOT develop tolerance?',
    choices: [
      { choiceId: 'a', text: 'Constipation', isCorrect: true, explanation: 'Tolerance to constipation does not develop; patients need ongoing laxatives.' },
      { choiceId: 'b', text: 'Respiratory depression', isCorrect: false, explanation: 'Tolerance to respiratory depression develops.' },
      { choiceId: 'c', text: 'Sedation', isCorrect: false, explanation: 'Tolerance to sedation develops within days.' },
      { choiceId: 'd', text: 'Nausea', isCorrect: false, explanation: 'Tolerance to nausea typically develops.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Tolerance to constipation does NOT develop.',
      detailed: 'Opioids decrease GI motility via mu receptors in the enteric nervous system. Unlike central effects (sedation, euphoria, respiratory depression), tolerance to constipation does not develop.',
      clinicalRelevance: 'All patients on chronic opioids need bowel regimen (stimulant laxative + stool softener). Methylnaltrexone treats opioid-induced constipation peripherally.',
      relatedConcepts: ['opioid side effects', 'constipation management', 'tolerance'],
    },
    tags: ['opioid', 'constipation', 'intermediate'],
    relatedTopicIds: ['opioid-side-effects', 'bowel-management'],
  },

  // PSYCHIATRIC MEDICATIONS
  {
    questionId: 'med-psych-001',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'nervous',
    difficulty: 2,
    questionText: 'SSRIs work by:',
    choices: [
      { choiceId: 'a', text: 'Blocking serotonin reuptake transporter (SERT)', isCorrect: true, explanation: 'SSRIs increase synaptic serotonin by blocking reuptake.' },
      { choiceId: 'b', text: 'Blocking dopamine receptors', isCorrect: false, explanation: 'Antipsychotics block dopamine receptors.' },
      { choiceId: 'c', text: 'Inhibiting monoamine oxidase', isCorrect: false, explanation: 'MAOIs inhibit monoamine oxidase.' },
      { choiceId: 'd', text: 'Enhancing GABA activity', isCorrect: false, explanation: 'Benzodiazepines enhance GABA activity.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'SSRIs block serotonin reuptake.',
      detailed: 'By blocking SERT on presynaptic neurons, SSRIs increase serotonin concentration in the synaptic cleft. Therapeutic effects take 4-6 weeks as downstream receptors adapt.',
      clinicalRelevance: 'First-line for depression and anxiety. Side effects: sexual dysfunction, GI upset, activation (early), serotonin syndrome (with other serotonergic drugs).',
      relatedConcepts: ['antidepressants', 'serotonin', 'depression treatment'],
    },
    tags: ['SSRI', 'antidepressant', 'intermediate'],
    relatedTopicIds: ['antidepressants', 'depression'],
  },
  {
    questionId: 'med-psych-002',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'nervous',
    difficulty: 2,
    questionText: 'First-generation antipsychotics (haloperidol) work primarily by:',
    choices: [
      { choiceId: 'a', text: 'Blocking D2 dopamine receptors', isCorrect: true, explanation: 'D2 blockade in mesolimbic pathway reduces positive symptoms.' },
      { choiceId: 'b', text: 'Blocking serotonin receptors', isCorrect: false, explanation: 'Second-generation antipsychotics have more serotonin blockade.' },
      { choiceId: 'c', text: 'Enhancing dopamine release', isCorrect: false, explanation: 'This would worsen psychosis.' },
      { choiceId: 'd', text: 'Blocking glutamate receptors', isCorrect: false, explanation: 'Glutamate modulation is a newer target.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'First-generation antipsychotics block D2 receptors.',
      detailed: 'D2 blockade in mesolimbic pathway reduces positive symptoms (hallucinations, delusions). However, D2 blockade in nigrostriatal pathway causes EPS, and in tuberoinfundibular pathway causes hyperprolactinemia.',
      clinicalRelevance: 'EPS: dystonia, akathisia, parkinsonism, tardive dyskinesia. NMS is a life-threatening complication. Treat acute dystonia with benztropine or diphenhydramine.',
      relatedConcepts: ['dopamine pathways', 'schizophrenia treatment', 'EPS'],
    },
    tags: ['antipsychotic', 'dopamine', 'intermediate'],
    relatedTopicIds: ['antipsychotics', 'schizophrenia'],
  },
  {
    questionId: 'med-psych-003',
    domain: 'pharmacology',
    type: 'side-effects',
    format: 'multiple-choice',
    system: 'nervous',
    difficulty: 3,
    questionText: 'Which monitoring is essential for patients on clozapine?',
    choices: [
      { choiceId: 'a', text: 'Absolute neutrophil count (ANC)', isCorrect: true, explanation: 'Clozapine causes agranulocytosis in ~1% of patients.' },
      { choiceId: 'b', text: 'Thyroid function', isCorrect: false, explanation: 'Thyroid monitoring is needed for lithium.' },
      { choiceId: 'c', text: 'Creatinine kinase', isCorrect: false, explanation: 'CK is checked if suspecting NMS or rhabdomyolysis.' },
      { choiceId: 'd', text: 'Coagulation studies', isCorrect: false, explanation: 'Clozapine does not affect coagulation.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Clozapine requires ANC monitoring for agranulocytosis.',
      detailed: 'Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia but carries a 1% risk of agranulocytosis. ANC monitoring is mandated: weekly for 6 months, then biweekly for 6 months, then monthly.',
      clinicalRelevance: 'Also causes significant metabolic effects (weight gain, diabetes), sedation, sialorrhea, and myocarditis. Reserved for refractory cases due to monitoring requirements.',
      relatedConcepts: ['agranulocytosis', 'treatment-resistant schizophrenia', 'atypical antipsychotics'],
    },
    tags: ['clozapine', 'monitoring', 'advanced'],
    relatedTopicIds: ['clozapine', 'drug-monitoring'],
  },

  // DIABETES MEDICATIONS
  {
    questionId: 'med-dm-001',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'endocrine',
    difficulty: 2,
    questionText: 'Metformin works primarily by:',
    choices: [
      { choiceId: 'a', text: 'Decreasing hepatic gluconeogenesis', isCorrect: true, explanation: 'Metformin reduces liver glucose production via AMPK activation.' },
      { choiceId: 'b', text: 'Stimulating insulin release', isCorrect: false, explanation: 'Sulfonylureas stimulate insulin release.' },
      { choiceId: 'c', text: 'Slowing carbohydrate absorption', isCorrect: false, explanation: 'Alpha-glucosidase inhibitors slow carb absorption.' },
      { choiceId: 'd', text: 'Increasing insulin sensitivity in muscle', isCorrect: false, explanation: 'TZDs primarily increase muscle insulin sensitivity.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Metformin decreases hepatic gluconeogenesis.',
      detailed: 'Metformin activates AMP-activated protein kinase (AMPK), which decreases hepatic glucose production. It also improves peripheral insulin sensitivity and may reduce intestinal glucose absorption.',
      clinicalRelevance: 'First-line for type 2 diabetes. Does not cause hypoglycemia. Main concern is lactic acidosis (rare, hold before contrast). GI side effects are common.',
      relatedConcepts: ['diabetes management', 'insulin resistance', 'AMPK'],
    },
    tags: ['metformin', 'diabetes', 'intermediate'],
    relatedTopicIds: ['diabetes-medications', 'oral-hypoglycemics'],
  },
  {
    questionId: 'med-dm-002',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'endocrine',
    difficulty: 2,
    questionText: 'SGLT2 inhibitors (empagliflozin) cause glucosuria by:',
    choices: [
      { choiceId: 'a', text: 'Blocking glucose reabsorption in the proximal tubule', isCorrect: true, explanation: 'SGLT2 inhibition causes glucose wasting in urine.' },
      { choiceId: 'b', text: 'Increasing insulin secretion', isCorrect: false, explanation: 'SGLT2i do not affect insulin secretion.' },
      { choiceId: 'c', text: 'Decreasing glucagon secretion', isCorrect: false, explanation: 'GLP-1 agonists decrease glucagon.' },
      { choiceId: 'd', text: 'Increasing glomerular filtration', isCorrect: false, explanation: 'SGLT2i may actually decrease GFR acutely.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'SGLT2i block glucose reabsorption in the kidney.',
      detailed: 'SGLT2 transporters in the proximal tubule reabsorb ~90% of filtered glucose. Blocking them causes glucose excretion in urine (~70 g/day), lowering blood glucose independent of insulin.',
      clinicalRelevance: 'Cardiovascular and renal benefits beyond glucose control. Side effects: UTIs, genital infections, euglycemic DKA. Now used in heart failure and CKD regardless of diabetes.',
      relatedConcepts: ['renal glucose handling', 'heart failure', 'diabetic kidney disease'],
    },
    tags: ['SGLT2i', 'diabetes', 'intermediate'],
    relatedTopicIds: ['SGLT2-inhibitors', 'cardiorenal-protection'],
  },

  // RESPIRATORY MEDICATIONS
  {
    questionId: 'med-resp-001',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'respiratory',
    difficulty: 1,
    questionText: 'Albuterol (short-acting beta-agonist) works by:',
    choices: [
      { choiceId: 'a', text: 'Relaxing bronchial smooth muscle via beta-2 receptors', isCorrect: true, explanation: 'Beta-2 stimulation causes bronchodilation.' },
      { choiceId: 'b', text: 'Blocking muscarinic receptors', isCorrect: false, explanation: 'Ipratropium blocks muscarinic receptors.' },
      { choiceId: 'c', text: 'Inhibiting leukotriene synthesis', isCorrect: false, explanation: 'Montelukast blocks leukotriene receptors.' },
      { choiceId: 'd', text: 'Reducing airway inflammation', isCorrect: false, explanation: 'Corticosteroids reduce inflammation.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Albuterol activates beta-2 receptors causing bronchodilation.',
      detailed: 'Beta-2 receptor activation increases cAMP in airway smooth muscle, causing relaxation and bronchodilation. Also inhibits mast cell mediator release. Onset is 5-15 minutes, duration 4-6 hours.',
      clinicalRelevance: 'Rescue inhaler for acute symptoms. Overuse indicates poor control. Side effects: tremor, tachycardia, hypokalemia (at high doses).',
      relatedConcepts: ['asthma treatment', 'bronchodilators', 'beta-agonists'],
    },
    tags: ['albuterol', 'bronchodilator', 'beginner'],
    relatedTopicIds: ['asthma-medications', 'COPD-medications'],
  },
  {
    questionId: 'med-resp-002',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'respiratory',
    difficulty: 2,
    questionText: 'Inhaled corticosteroids (fluticasone) treat asthma by:',
    choices: [
      { choiceId: 'a', text: 'Reducing airway inflammation', isCorrect: true, explanation: 'ICS decrease inflammatory cell infiltration and cytokine production.' },
      { choiceId: 'b', text: 'Directly relaxing smooth muscle', isCorrect: false, explanation: 'ICS are not bronchodilators.' },
      { choiceId: 'c', text: 'Blocking histamine receptors', isCorrect: false, explanation: 'Antihistamines block histamine receptors.' },
      { choiceId: 'd', text: 'Inhibiting mast cell degranulation', isCorrect: false, explanation: 'Cromolyn inhibits mast cell degranulation.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'ICS reduce airway inflammation.',
      detailed: 'Corticosteroids decrease eosinophil, mast cell, and T-cell infiltration. They reduce production of inflammatory cytokines and increase beta-receptor expression. They are the most effective controller for persistent asthma.',
      clinicalRelevance: 'First-line controller for persistent asthma. Takes days-weeks for full effect. Local side effects: hoarseness, oral candidiasis (rinse mouth after use).',
      relatedConcepts: ['asthma control', 'anti-inflammatory', 'controller medications'],
    },
    tags: ['ICS', 'asthma', 'intermediate'],
    relatedTopicIds: ['asthma-controllers', 'corticosteroids'],
  },

  // GI MEDICATIONS
  {
    questionId: 'med-gi-001',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'digestive',
    difficulty: 1,
    questionText: 'Proton pump inhibitors (omeprazole) work by:',
    choices: [
      { choiceId: 'a', text: 'Irreversibly blocking H+/K+-ATPase', isCorrect: true, explanation: 'PPIs block the final step of acid secretion.' },
      { choiceId: 'b', text: 'Blocking histamine H2 receptors', isCorrect: false, explanation: 'H2 blockers (famotidine) block H2 receptors.' },
      { choiceId: 'c', text: 'Neutralizing gastric acid', isCorrect: false, explanation: 'Antacids neutralize acid.' },
      { choiceId: 'd', text: 'Coating the gastric mucosa', isCorrect: false, explanation: 'Sucralfate coats ulcers.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'PPIs irreversibly block the gastric proton pump.',
      detailed: 'PPIs are prodrugs activated in the acidic parietal cell canaliculus. They covalently bind and irreversibly inhibit H+/K+-ATPase. Since they are irreversible, acid suppression lasts until new pumps are made (24-48 hours).',
      clinicalRelevance: 'Most effective acid suppressants. Long-term risks: hypomagnesemia, B12 deficiency, C. diff, osteoporosis, pneumonia. Take before meals.',
      relatedConcepts: ['acid suppression', 'GERD treatment', 'peptic ulcer disease'],
    },
    tags: ['PPI', 'acid-suppression', 'beginner'],
    relatedTopicIds: ['acid-suppression', 'GERD'],
  },
  {
    questionId: 'med-gi-002',
    domain: 'pharmacology',
    type: 'drug-mechanism',
    format: 'multiple-choice',
    system: 'digestive',
    difficulty: 2,
    questionText: 'Ondansetron prevents nausea by blocking which receptor?',
    choices: [
      { choiceId: 'a', text: '5-HT3 (serotonin) receptors', isCorrect: true, explanation: 'Ondansetron blocks 5-HT3 receptors in CTZ and GI tract.' },
      { choiceId: 'b', text: 'Dopamine D2 receptors', isCorrect: false, explanation: 'Metoclopramide and prochlorperazine block D2 receptors.' },
      { choiceId: 'c', text: 'Histamine H1 receptors', isCorrect: false, explanation: 'Diphenhydramine and promethazine block H1.' },
      { choiceId: 'd', text: 'Muscarinic receptors', isCorrect: false, explanation: 'Scopolamine blocks muscarinic receptors.' },
    ],
    correctAnswer: 'a',
    explanation: {
      brief: 'Ondansetron blocks 5-HT3 receptors.',
      detailed: 'Serotonin released from enterochromaffin cells during chemotherapy stimulates 5-HT3 receptors on vagal afferents and in the chemoreceptor trigger zone, causing nausea. Ondansetron blocks this.',
      clinicalRelevance: 'Very effective for chemotherapy and post-operative nausea. Can cause QT prolongation, constipation, and headache. Less effective for motion sickness.',
      relatedConcepts: ['antiemetics', 'chemotherapy side effects', 'nausea mechanisms'],
    },
    tags: ['ondansetron', 'antiemetic', 'intermediate'],
    relatedTopicIds: ['antiemetics', 'nausea-vomiting'],
  },
];

export const allMedicationQuestions: QuizQuestion[] = [
  ...medicationQuestions,
];
